HUMA · Stage, GEX levels and seasonality

Humacyte, Inc. Common Stock (HUMA)

Last close $0.52 (-2.82%) on 2026-09-30

Start 7-day trial

No card. The trial ends after 7 days unless you choose a paid plan. There is no automatic charge.

Open the chart

Weinstein stage

Stage 4B — Declining · 39 weeks in this stage · 30-week average $0.80

Stage 4 (declining): price stays below a falling 30-week average. The stage Weinstein avoids.

What would change it: Stage 1 begins when the 30-week SMA (0.8) stops declining and price starts closing above it.

GEX levels

Call wall, put wall and gamma flip for HUMA are on Signa plans. What GEX levels tell you.

Seasonality

MonthAverage returnMonths upYears
January+15.36%75%4
February-4.66%25%4
March-27.08%0%4
April+19.22%75%4
May+58.76%100%4
June-28.81%0%4
July+18.06%50%4
August-8.93%25%4
September-3.8%25%4
October (this month)-15.21%0%3
November-5.16%33%3
December-2.73%67%3

Based on up to 4 years of weekly closes. Past seasonality does not predict future returns.

On Signa plans

The Signa score and Action Card for HUMA, live options flow, dark pool prints, today's GEX levels with vanna and charm, and what 40+ AI agents say about it.

Start 7-day trial

No card. The trial ends after 7 days unless you choose a paid plan. There is no automatic charge.

Questions about HUMA

What Weinstein stage is HUMA in?

HUMA is in Stage 4B — Declining, for 39 weeks, based on completed weekly bars and its 30-week moving average (0.80).

How has HUMA done in October?

Over the last 3 years, HUMA averaged -15.21% in October and rose in 0% of them. Past seasonality does not predict future returns.

Start 7-day trial

No card. The trial ends after 7 days unless you choose a paid plan. There is no automatic charge.